Platinum-based anticancer drugs, represented by cisplatin, play important roles in present cancer chemotherapy. Although three or five platinum-based drugs have been approved for clinical use worldwide or in Japan, many active researches are still ongoing to seek next generation platinum-based drugs with less side effect and higher efficacy. Tetrazolato-bridged dinuclear platinum(II) complexes (tetrazolato-bridged complex) are distinctively different from existing platinum-based drugs in cytotoxicity spectra, DNA interactions, and cellular uptake profiles, probably due to their unique structures. Tetrazolato-bridged complexes provide high in vivo antitumor activity toward pancreatic cancer which is difficult to cure. In this review, we introduce the recent drug development researches on platinum-based drugs and update the latest findings of tetrazolato-bridged complex.
展开▼
